Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 22;121(2):227-229.
doi: 10.1093/cvr/cvae266.

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial

Giulio Stefanini  1   2 , Carmelo Carlo-Stella  1   2 , Francesco Cannata  1   2 , Mauro Chiarito  1   2 , Stefano Figliozzi  1   2 , Laura Novelli  1   2 , Costanza Lisi  1   2 , Sara Bombace  1   2 , Federica Catapano  1   2 , Eleonora Indolfi  1   2 , Cristina Panico  1   2 , Francesco Corrado  1   2 , Giovanna Masci  1   2 , Rita Mazza  1   2 , Francesca Ricci  1   2 , Lorenzo Monti  1   2 , Giuseppe Ferrante  1   2 , Bernhard Reimers  1   2 , Armando Santoro  1   2 , Marco Francone  1   2 , Bruno R da Costa  3 , Peter Jüni  3 , Gianluigi Condorelli  1   2
Affiliations

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial

Giulio Stefanini et al. Cardiovasc Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none declared.

Figures

Figure 1
Figure 1
(A) Study flowchart. (B) The primary endpoint is LVEF reduction at 12 months, based on an ANCOVA model with LVEF at 12 months as dependent variable and treatment and LVEF at baseline as independent variables. (C and D) Troponin and NT-pro-BNP values over time were compared between groups using ANCOVA model. (E) Survival curve for CTRCD; compared between groups using a χ2 test. (F) Primary endpoint stratified by key subgroups; based on an ANCOVA model with LVEF at 12 months as dependent variable and treatment and LVEF at baseline as independent variables.
See this image and copyright information in PMC

References

    1. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474–502. - PMC - PubMed
    1. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, Lancellotti P, Thuny F, Abdelhamid M, Aboyans V, Aleman B, Alexandre J, Barac A, Borger MA, Casado-Arroyo R, Cautela J, Čelutkienė J, Cikes M, Cohen-Solal A, Dhiman K, Ederhy S, Edvardsen T, Fauchier L, Fradley M, Grapsa J, Halvorsen S, Heuser M, Humbert M, Jaarsma T, Kahan T, Konradi A, Koskinas KC, Kotecha D, Ky B, Landmesser U, Lewis BS, Linhart A, Lip GYH, Løchen M-L, Malaczynska-Rajpold K, Metra M, Mindham R, Moonen M, Neilan TG, Nielsen JC, Petronio A-S, Prescott E, Rakisheva A, Salem J-E, Savarese G, Sitges M, Berg Jt, Touyz RM, Tycinska A, Wilhelm M, Zamorano JL, Laredj N, Zelveian P, Rainer PP, Samadov F, Andrushchuk U, Gerber BL, Selimović M, Kinova E, Samardzic J, Economides E, Pudil R, Nielsen KM, Kafafy TA, Vettus R, Tuohinen S, Ederhy S, Pagava Z, Rassaf T, Briasoulis A, Czuriga D, Andersen KK, Smyth Y, Iakobishvili Z, Parrini I, Rakisheva A, Pruthi EP, Mirrakhimov E, Kalejs O, Skouri H, Benlamin H, Žaliaduonytė D, Iovino A, Moore AM, Bursacovschi D, Benyass A, Manintveld O, Bosevski M, Gulati G, Leszek P, Fiuza M, Jurcut R, Vasyuk Y, Foscoli M, Simic D, Slanina M, Lipar L, Martin-Garcia A, Hübbert L, Kurmann R, Alayed A, Abid L, Zorkun C, Nesukay E, Manisty C, Srojidinova N, Baigent C, Abdelhamid M, Aboyans V, Antoniou S, Arbelo E, Asteggiano R, Baumbach A, Borger MA, Čelutkienė J, Cikes M, Collet J-P, Falk V, Fauchier L, Gale CP, Halvorsen S, Iung B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis BS, Linhart A, Løchen M-L, Mindham R, Nielsen JC, Petersen SE, Prescott E, Rakisheva A, Sitges M, Touyz RM, . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229–4361. - PubMed
    1. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, Chandra A, Haykowsky M, Ky B, Moslehi J, Nohria A, Butler J, Pandey A. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol 2019;1:54–65. - PMC - PubMed
    1. Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 2021;143:2431–2440. - PMC - PubMed
    1. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355–2362. - PubMed